View text source at Wikipedia
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Pharmacokinetic data | |
Metabolism | Hepatic (CYP2C19-mediated) |
Elimination half-life | 4.8 to 7.7 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.120.697 |
Chemical and physical data | |
Formula | C16H18N4O3S |
Molar mass | 346.41 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(verify) |
Tenatoprazole is a proton pump inhibitor drug candidate that was undergoing clinical testing as a potential treatment for reflux oesophagitis and peptic ulcer as far back as 2003.[1] The compound was invented by Mitsubishi Tanabe Pharma and was licensed to Negma Laboratories (part of Wockhardt as of 2007[2]).[3]: 22
Mitsubishi reported that tenatoprazole was still in Phase I clinical trials in 2007[4]: 27 and again in 2012.[3]: 17
Tenatoprazole has an imidazopyridine ring in place of the benzimidazole moiety found in other proton pump inhibitors, and has a half-life about seven times longer than other PPIs.[5]